Core Viewpoint - The company, Baoji Pharmaceutical, is set to launch an IPO from December 2 to December 5, 2025, aiming to raise funds through the issuance of 37.9117 million shares, with a maximum public offering price of HKD 26.38 per share, and is expected to be listed on the Hong Kong Stock Exchange on December 10, 2025 [1] Group 1: IPO Details - The IPO will consist of 10% of shares available for public sale in Hong Kong and 90% for international sale [1] - Three cornerstone investors, including Anke Bio, DC Alpha SPC, and Guotai Junan Securities, have committed to subscribe for a total of HKD 200.6 million, representing approximately 21.77% of the total fundraising amount [1] Group 2: Company Overview - The company is a clinical and commercial-stage biotechnology firm focused on four key areas: antibody-mediated autoimmune diseases, large-volume subcutaneous injections, assisted reproductive drugs, and transformative products that replace traditional biochemical extraction methods [1] - Currently, the company has seven clinical-stage candidate drugs and seven selected preclinical-stage candidate drugs [1] Group 3: Core Products - The core product KJ017 is a recombinant hyaluronidase designed for large-volume subcutaneous delivery of macromolecular drugs and has submitted a listing application [1] - KJ103 is in phase three clinical trials for the treatment of various autoimmune diseases [1] - SJ02 is the first long-acting follicle-stimulating hormone approved for marketing in China, reducing the treatment cycle from daily injections to once a week [1]
宝济药业-B今日起招股 预计12月10日在港交所上市
Zheng Quan Shi Bao·2025-12-02 01:24